Macromoltek
macromoltek.com
Actively hiring
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Y Combinator
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 2018
Went through Y Combinator
Tractionpublic signals, read monthly
Web presence
top 5%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Y Combinator Similar startupsby what they do, their industry and backers
KisoJi Biotechnology. Breakthrough antibody discovery forbreakthrough therapeutics.
immunitoAI is an AI-driven biotechnology company accelerating antibody discovery and the development of antibody-based therapies through…
Antiverse combines generative AI and advanced antibody discovery to design functional, developable biologics for challenging drug targets.
Alloy Therapeutics democratizes access to antibody discovery and biologics discovery technology to enable and advance drug discovery in…
Mosaic Biosciences is an integrated biologic discovery CRO specializing in antibody discovery, protein engineering, function-first…
Viridian Therapeutics is leveraging core expertise in antibody discovery to develop optimized treatments for rare autoimmune conditions.
Overview
Advanced Antibody Design Services. Macromoltek harnesses the power of computational modeling and artificial intelligence to accelerate and optimize the antibody discovery and engineering process.
News
Cytovia Therapeutics and Macromoltek
Candidate: Natural Killer (NK) immunotherapy targeting SARS-CoV-2 Type: NK cells leveraging Cytovia's proprietary bi-functional technology, developed by co-founder Jean Kadouche, PhD. and novel antibodies neutralizing or blocking SARS CoV2, designed by Ma
Read more
Report
Macromoltek Deploys Computational Design Platform To Enable Cytovia Therapeutics Drug Development For COVID-19
Read more
Report
CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19)
Read more
Report
CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19)
Read more
Report
Macromoltek Announces Computational De Novo Antibody Design Offering, Targeting COVID-19
/PRNewswire/ -- Macromoltek, Inc. today announced computational de novo design capability to speed up the development of human monoclonal antibodies for the...
Read more
Report
Pro access
Upgrade to see all 9 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.